MedTrace Logo

Erythropoietin (EPO) and Ischemia-reperfusion After Kidney Transplantation

NCT00425698 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 88

Last updated 2010-09-28

Study results available
· View outcomes & findings →

Summary

The hematopoetic cytokine erythropoietin (EPO) has been shown to reduce programmed cell death and tissue destruction in experimental models of acute kidney ischemia-reperfusion injury. Thus, treatment with high dose recombinant human EPO (rHuEPO) may prevent kidney tissue damage and loss of renal function after successful kidney transplantation in humans.

Conditions

  • Kidney Transplantation

Interventions

DRUG

Recombinant erythropoietin alpha (rHuEPO alpha)

Erythropoietin alpha 3 x 40.000 IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

DRUG

Placebo

Placebo 3x IU intraarterial or intravenous within 7 days after cadaveric kidney transplantation

Sponsors & Collaborators

  • Hannover Medical School

    lead OTHER

Principal Investigators

  • Danilo Fliser, MD · Saarland University Medical Centre

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-02-28
Primary Completion
2009-05-31
Completion
2009-11-30

Countries

  • Germany

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00425698 on ClinicalTrials.gov